Insurance startup Lemonade sets a price range of $23 to $26 for its IPO, valuing it ~$1.3B, about 25% less than its $2B valuation in its last funding round
Graham Rapier / Business Insider :
Context & Ripple Effects
Lemonade's road to this pricing was a steady private-market climb: a $13M seed from Aleph and Sequoia in 2015, another $33.1M disclosed in SEC filings a year later, then a $120M Series C led by SoftBank at a reported $500M+ valuation, culminating in $480M raised across five rounds with the last one at $2B+. The S-1 behind this offering showed the gap between that story and the numbers — $67.3M of revenue against a $108.5M net loss for 2019.
Pricing at $23–$26 implies roughly $1.3B, an explicit haircut of about 25% to the prior round's $2B+ — a rare public concession by a hot consumer startup that its private mark didn't survive contact with public-market discipline.
First-order effects
- SoftBank and earlier backers Aleph and Sequoia are selling into a discount: at $1.3B, their paper gains from the $500M-plus Series C and the $2B+ final private round compress unless the book builds.
- Lemonade locks in roughly $1.3B of valuation on thin fundamentals — $67.3M revenue against a $108.5M loss — trading the freedom of a private cap table for quarterly scrutiny of that loss ratio.
Second-order effects
- A first-day repricing upward would hand late-round investors a face-saving narrative — 'priced conservatively, popped anyway' — and the market delivered exactly that with a 140% NYSE debut close at a $3.93B market cap, more than double even SoftBank's 2019 valuation.
- Other venture-backed insurtechs approaching the window now have a template: price deliberately below the last private mark to guarantee a pop rather than defend the private number and risk a flat or down debut.
Third-order effects
- If the pattern holds, the millennial-friendly, AI-native insurance cohort faces a structural test: public markets will value loss-making growth insurers on unit economics, not story, forcing either faster paths to profitability or lower entry valuations across the category.
- The episode sharpens the evergreen tension between private marks and public clearing prices — funds marking portfolio companies at round valuations will face harder questions when IPO pricing routinely lands 20–30% below the last raise.
The trend: Venture-backed consumer insurtechs are entering public markets through discounted IPO pricings that reset private valuations downward before first-day pops restore them, exposing the gap between fund marks and what public buyers will pay for loss-making growth.